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ABSTRACT: XJP-L (8), a derivative of the natural product (±)-7,8-dihydroxy-3-methylisochroman-4-one isolated from the peel of 
Musa sapien tum L., was found to exhibit weak inhibitory activity of tubulin polymerization (IC50 = 10.6 µM) in our previous 
studies. Thus, a series of 4-arylisochromene derivatives were prepared by incorporating the trimethoxyphenyl moiety into 8. 
Among which, compound (±)-19b was identified as the most potent compound with IC50 values ranging from 10 to 25 nM against a 
panel of cancer cell lines. Further mechanism studies demonstrated that  (±)-19b disrupted the intracellular microtubule network, 
caused G2/M phase arrest, induced cell apoptosis and depolarized mitochondria of K562 cells. Moreover, (±)-19b exhibited potent 
in vitro anti-vascular and in vivo anti-tumor activities. Notably, the R-configured enantiomer of (±)-19b, which was prepared by 
chiral separation, was slightly more potent than (±)-19b and was much more potent than the S-configured enantiomer in both anti-
proliferative and anti-tubulin assays. Our findings suggest that (±)-19b deserves further research as a potential anti-tubulin agent for 
the treatment of cancers. 
Combretastatin A-4 (1, CA-4) (Figure 1), a natural cis- stil-
bene derivative isolated from the bark of the African willow 
tree Combretum caffrum,
1
 was found to be a powerful inhibi-
tor of tubulin polymerization targeting the colchicine binding 
site.
2
 CA-4 has strong cytotoxicity against a variety of tumor 
cells with a broad therapeutic window. Besides, CA-4 was 
reported to show vascular disrupting properties at a tolerated 
dose.
3 
The potent antimitotic and vascular disrupting profiles 
of CA-4 made it a promising therapy for the treatment of can-
cers.
4-7
 However, CA-4P (2, Fosbretabulin), the phosphate 
prodrug of CA-4, had been discontinued in clinical trials
8
 due 
to the lack of a meaningful improvement in progression-free 
survival (PFS) and unfavorable partial response data.
9
 In the 
presence of light, heat or acid media, but also after in vivo 
administration, the Z-isomer of CA-4 easily isomerizes to the 
E-isomer that is significantly less potent at inhibiting tubulin 
polymerization and cancer cell growth.
10
 Strategies to sur-
mount this drawback have been taken by modification on the 
bridge structure of CA-4, which lead to the discovery of vari-
ous moieties replacing the cis-double bond.
11-13
 Fusing cis-
olefin into the ring B represents an important tactic to lock the 
cis double bond, compounds 3-6 with highly potent cytotoxici-
ty were thus discovered (Figure 1).
14-21
  
It is known to all that natural products with structurally di-
verse frameworks have always been and continue to be an 
important source for new drug discovery.
22
 (±)-7,8-Dihydroxy-
3-methylisochroman-4-one [7, (±)-XJP] was a structurally 
unique 4-isochromanone compound which was isolated from 
the peel of Musa sapientum L. and total synthesized by our 
group,
23,24
 and it exhibited a wide range of favorable pharma-
cological properties.
25, 26
 In our previous research for discover-
ing new anti-tubulin agents with novel skeletons, a series of 
XJP derivatives was screened for their inhibitory activity of 
tubulin polymerization. Interestingly, XJP-L (8) was found to 
exhibit weak microtubule polymerization inhibitory activity 
(IC50 = 10.6 µM).  
Considering the vital roles of 3,4,5-trimethoxyphenyl on the 
activity of inhibitors of tubulin polymerization targeting the 
colchicine binding site,
27-29
 8 was further hybridized with 
3,4,5-trimethoxyphenyl moiety for improving both its anti-
proliferative and inhibitory activities of tubulin polymerization 
using the cis-double bond locking strategy. Thus, a series of 
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novel 4-arylisochromenes were designed and synthesized 
(Figure 1). Herein, we wish to report their synthesis and anti-
tumor activities as anti-tubulin agents. 
The synthetic route for the preparation of 4-
arylisochromenes is outlined in Scheme 1. Various substituted 
XJP scaffolds 12a-e were synthesized according to the method 
utilizing a Parham-type cyclization with the tert-butyllithium 
reagent reported by our group.
30
 Sulphur-containing XJP scaf-
folds 12f-g were further synthesized via a Friedel-Crafts cyclic 
reaction. 
 
 
Figure 1. The strategy of fusing the bridge into ring B of CA-4 to sur-
mount its instability and the design of XJP derived tubulin inhibitor.
 
Then, 12a-g were transformed into their corresponding N-
tosylhydrazones 15a-g in refluxing EtOH with good to excel-
lent yields, followed by the coupling of 15a-g with 5-bromo-
1,2,3-trimethoxybenzene (16) via a Pd-catalyzed cross-
coupling to afford 17a-g in moderate to good yields. Utilizing 
the different reducing capacity of Pd-C/H2 in THF and CH3OH, 
benzyl group of 17b and 17d were selectively deprotected 
using THF as the solvent to give compound 18a and 18b, re-
spectively, while double bonds were reduced to afford (±)-
19a-d with CH3OH as the solvent. 
All target compounds 17a, 17c, 17e-g, 18a-b and (±)-19a-d 
were initiatively evaluated for their anti-proliferative activities 
against human hepatocellular carcinoma cells (HepG2) by the 
MTT assays. Most of the synthesized compounds displayed 
potent activity against HepG2 cells and the preliminary struc-
ture activity relationships (SARs) were obtained. The position 
of hydroxyl group on the isochroman moiety was crucial for 
anti-proliferative activity. Compound 18b and (±)-19b, which 
contain hydroxyl at the C-5 position (R2), exhibited the most 
potent activity with IC50 values of 26 and 15 nM, respectively. 
Moving the OH group from C-5 position to C-3 position led to 
the loss of anti-proliferative activity (18a and 19d, IC50 > 10 
µM). When R2 was substituted with other groups such as 
OCH3 [17c and (±)-19c], Br (17e) or no substitution [17a and 
(±)-19a], the activity significantly decreased when compared 
with 18b and (±)-19b. Besides, the activity was maintained 
when sulfur (X = S) was introduced into the isochroman scaf-
fold (17f and 17g). The reduction of double bonds led to a 
slightly improvement of activity [17a vs 19a, 17c vs (±)-19c 
and 18b vs (±)-19b]. Especially, compound (±)-19b displayed 
the most potent anti-proliferative activity (IC50 = 15 nM), 
which exhibited nearly 1000-fold improvement of activity 
towards 8 (IC50 = 23.7 µM) (See Supporting Information Table 
S1). 
Scheme 1. Synthetic route to 4-arylisochromenes
a
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aReagents and conditions: (a) NaH, DMF, 2h, 55-70%; (b) t-BuLi, THF, 
-78 oC, 15min, 72-90%; (c) i) ethyl thioglycolate, K2CO3, CH3CN, 2h, 75-
88%; ii) 10% NaOH aqueous, CH3OH, 80 
oC, 85-90%; (d) i) oxalyl chlo-
ride, DMF(cat.), DCM; ii) SnCl4, chlorobenzene, 55-65% over two steps; 
(e) p-Toluenesulfonhydrazide, EtOH, 90 oC, 75-90%; (f) 5-bromo-1,2,3-
trimethoxybenzene (16), PdCl2(CH3CN)2, Xphos, t-BuOLi, 90 
oC, 45-70%; 
(g) Pd/C, H2, THF, 65-92%; (h) Pd/C, H2, CH3OH, 72-95%.
 
Subsequently, compounds 18b and (±)-19b were further 
evaluated for their anti-proliferative activity against another 
five cancer cell lines including KB, HCT-8, MDA-MB-231, 
K562 and H22 cells. As shown in Table 1, both 18b and (±)-
19b showed potent anti-proliferative activities. Especially, (±)-
19b exhibited the most active against K562 cell lines with the 
IC50 value of 10 nM, which is more potent than the positive 
control CA-4 (IC50 = 15 nM); Human normal hepatocytes LO2 
cells were also used to determine their selectivity towards 
cancer cells and normal cells, which showed that 18b and (±)-
19b selectively inhibited the growth of cancer cells.  
The further in vitro assay for the inhibition of tubulin 
polymerization demonstrated that compounds 18b and (±)-19b 
were potent inhibitors of tubulin polymerization. As shown in 
Table 1, compound (±)-19b (IC50 = 3.1 µM) was more potent 
than 18b (IC50 = 4.2 µM) and was slightly less potent than CA- 
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Table 1. Cytotoxicity against five cancer cell lines, Human normal hepatocytes LO2 cells and ITP of compounds 18b, (±)-
19b, (R)-(+)-19b and (S)-(-)-19b
a
 
Compd. 
 IC50 values (µM)  
KB HCT-8 
MDA-MB 
-231 
K562 H22 LO2 ITP
b
 
18b 0.016±0.002 0.025±0.004 0.028±0.004 0.019±0.002 0.010±0.001 0.138±0.012 4.2±0.3 
(±)-19b 0.025±0.002 0.030±0.002 0.022±0.002 0.010±0.001 0.011±0.001 0.095±0.010 3.1±0.2 
(R)-(+)-19b 0.012±0.002 0.012±0.001 0.011±0.002 0.008±0.001 0.008±0.002 0.058±0.005 2.5±0.1 
(S)-(-)-19b 0.87±0.08 0.94±0.12 0.90±0.09 0.46±0.06 0.80±0.12 0.90±0.08 4.3±0.1 
CA-4 0.012±0.001 0.015±0.002 0.015±0.002 0.015±0.002 0.008±0.001 0.095±0.002 2.5±0.2 
8 25.1±0.9 35.2±1.3 30.2±2.0 20.5±1.2 18.2±2.1 22.2±1.2 10.6±0.2 
aMTT methods; cells were incubated with indicated compounds for 72 h (means ± SD, n = 3). 
b Inhibition of tubulin polymerization activity.  
-4 (IC50 = 2.5 µM). Furthermore, (±)-19b exhibited nearly 3-
fold improvement of inhibitory activity of tubulin polymeriza-
tion compared with 8 (IC50 = 10.6 µM), which suggested that 
the trimethoxyphenyl moiety has significant roles in binding 
with tubulin. In addition, in assay of the colchicine competi-
tive experiment, the binding potency of (±)- 19b to the colchi-
cine binding site was comparable to that of CA-4 with the 
inhibition rates of 76.4% and 89.6% at 1 µM and 5 µM, re-
spectively (see Supporting Information Table S2), indicating 
that (±)-19b binds to the colchicine binding site. 
Moreover, immunofluorescent assays were performed to in-
vestigate the effect of (±)-19b on microtubule networks. As 
shown in Figure 2, K562 cells exhibited normal filamentous 
microtubules arrays without drug treatment. However, after 
exposure to (±)-19b at three different concentrations (5 nM, 
10 nM, 20 nM) for 24 h, the microtubule networks in cytosol 
were disrupted, indicating that (±)-19b induced a dose-
dependent collapse of the microtubule networks.  
Since most microtubule polymerization inhibitors disrupt 
cell mitosis and exert cell cycle arrest effects,
31 
the effect of 
(±)-19b on cell cycle progression using propidiumiodide (PI) 
staining in K562 cells was examined. When treated with (±)-
19b at 5 nM, 10 nM, 20 nM for 48 h, the percentages of cells 
arrested at the G2/M phase were 17.5%, 19.5%, and 22.4%, 
respectively, indicating that (±)-19b can disrupt the dynamic 
balance of the tubulin-microtubule system and further induced 
the cell cycle arrest at the G2/M phase (see Supporting Infor-
mation Figure S1). Next, an Annexin V-APC/7-AAD binding 
assay was carried out to assess whether (±)-19b would induce 
cell apoptosis. The percentage of apoptotic cells after the 48 h 
treatment was only 5.7% in the control group. The total num-
bers of early (Annexin-V+/PI−) and late (Annexin-V+/PI+) 
apoptotic cells increased to 13.7%, 29.0% and 54.1% after 
treatment with (±)-19b at 5, 10, 20 nM for 48 h, respectively 
(see Supporting Information Figure S2). These results con-
firmed that (±)-19b effectively induced cell apoptosis in K562 
cells in a dose-dependent manner. 
In order to determine whether (±)-19b-induced apoptosis 
was involved in a disruption of mitochondrial membrane in-
tegrity, the fluorescent probe JC-1 was employed to measure 
the mitochondrial membrane potential (MMP). When treated 
with (±)-19b at concentrations of 0, 5, 10 and 20 nM for 48 h, 
the number of K562 cells with collapsed MMP increased to 
0.6%, 12.7%, 26.7% and 55.1%, respectively (see Supporting 
Information Figure S3), suggesting that (±)-19b caused mito-
chondrial depolarization of K562 cells in the process of apop-
tosis. 
Most microtubule binding agents have antiangiogenic or 
vascular-disrupting activities or both, which are   anti-vascular 
effects.
32
 Angiogenesis inhibiting agents (AIAs) interfere with 
new vessel formation, require chronic administration, and are 
likely to be of benefit in early-stage or asymptomatic metastat-
ic disease. While vascular-disrupting agents (VDAs) target the 
 
Figure 2. Effects of (±)-19b on the cellular microtubule network visual-
ized by immunofluorescence. 
 
established tumor blood vessels, which are often given acutely 
and have particular efficacy against advanced disease.
33
 Con-
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4
sidering that invasion and tube formation are highly relevant 
properties in the process of tumor vasculature, the HUVEC 
culture assay was used to assess the ability of (±)-19b to inhib-
it HUVEC migration. As a result, the untreated cells migrated 
to fill the area that was initially scraped after 24 h. In contrast, 
(±)-19b significantly inhibited the HUVEC migration in a 
dose-dependent manner (see Supporting Information Figure 
S4A). Then we further evaluated the anti-vascular ability of 
(±)-19b in a tube formation assay. After being seeded on mat-
rigel, HUVECs form the capillary-like tubules with multicen-
tric junctions. After exposure to (±)-19b at doses of 0, 5, 10, 
and 20 nM for 6 h, the capillary-like tubes were interrupted in 
different levels (Figure S4B). These results showed that (±)-
19b effectively inhibited the tube formation of HUVECs.  
Furthermore, we tested the in vivo anti-tumor activity of 
(±)-19b based on the in vitro anti-proliferative activity and 
mechanistic studies. Mouse liver cancer xenograft model was 
established by subcutaneous inoculation of H22 cells into the 
right flank of mice. The tumor size and body weights of the 
mice were monitored and recorded every 2 days. Paclitaxel 
(PTX) was dosed as 8 mg/kg per 2 days (i.v.) due to its severe 
toxicity. To compare the anti-tumor efficacy of (±)-19b and 
CA-4, (±)-19b and CA-4 were dosed at 15 and 30 mg/kg per 
day (i.v.). None of the mice died in all groups after 21 days 
treatments. As shown in Figure 3A, both (±)-19b at the dose 
of 30 mg/kg per day and PTX at the dose of 8 mg/kg per 2 
days significantly decreased the tumor volume. The reduction 
in tumor weight of PTX group reached 72.1% at 21 days after 
initiation of treatment as compared to vehicle, while (±)-19b 
reduced tumor weight by 46.5% and 62.3% at doses of 15 and 
30 mg/kg per day (i.v.), respectively, which are more potent 
than CA-4 treatment groups (inhibitory rates of 44.8% and 
55.3% at doses of 15 and 30 mg/kg per day, respectively) 
(Figure 3C). Importantly, (±)-19b did not significantly affect-
ed body weight even at the dose up to 30 mg/kg, while treat-
 
 
Figure 3. A) Tumor growth curves after injection with different 
formulations in H22 tumor bearing mice. B) Body weight 
changes of mice during treatment. C) (±)-19b treatment result-
ed in significantly lower tumor weight compared with controls.
 
-ment with PTX at a dose of 8 mg/kg per 2 days led to a sig-
nificant decrease of body weight (Figure 3B). Thus, (±)-19b is 
worthy of further investigation for the treatment of cancers. 
Finally, in order to investigated the effects of C-4 chirality 
on activity, the racemic mixture of (±)-19b were enantiosepa-
rated on a chiral column (see supporting information Figure 
S5) to afford (+)-19b and (-)-19b. Circular dichroism (CD) 
was performed to determine the absolute configuration, and 
the results indicated that the absolute configuration of (+)-19b 
is R-configured and the absolute configuration of (-)-19b is S-
configured (see supporting information Figure S6). 
Furthermore, (R)-(+)-19b and (S)-(-)-19b were evaluated 
for their anti-proliferative and inhibitory activities of tubulin 
polymerization. As shown in Table 1, the R-configured 19b 
still exhibited very potent activity against five cancer cell lines, 
which were slightly potent than (±)-19b, whereas (S)-(-)-19b 
displayed a significant decrease of activity. As regard to the 
anti-tubulin assays, (R)-(+)-19b (IC50 = 2.5 µM) was about 2--
fold more potent than (S)-(-)-19b (IC50 = 4.3 µM). Moreover, 
in assay of the colchicine competitive experiment, the binding 
ability of (R)-(+)-19b to the colchicine binding site was more 
potent than (±)-19b, and was comparable to that of CA-4 with 
the inhibition rates of 79.4% and 92.6% at 1 µM and 5 µM 
(Table S2). 
To explain the significant difference in activity for two en-
antiomers of (±)-19b, molecular modeling studies were per-
formed by using the DOCK program in Discovery Studio 3.0 
software with the tubulin crystal structure (PDB: 5lyj). As a 
result, (R)-(+)-19b adopted a very similar positioning with 
that of CA-4. The phenolic hydroxyl and 4-methoyl of (R)-
(+)-19b and CA-4 formed hydrogen bonds with Thr179 and 
Cys241 residues, respectively. The oxygen atom in iso-
chromene ring interacted with residue Asn258 by a weak hy-
drogen bond (see Supporting Information Figure S7A). How-
ever, the binding pose of (S)-(-)-19b was flipped over 180° 
compared to that of CA-4, which may explain why both the 
anti-tubulin and anti- proliferative activity of (S)-(-)-19b de-
creased dramatically (Figure S7B). 
In summary, a series of novel 4-arylisochromenes have 
been synthesized based on the structure of XJP-L (8). Anti-
proliferative screening of these new synthesized compounds 
validated the representative compound (±)-19b as a high cyto-
toxic compound with IC50 ranging from 10 to 25 nM against a 
panel of cancer cell lines, which displayed a 1000-fold in-
crease in activity compared with the lead 8. It was found that 
(±)-19b also displayed potent inhibitory activity in tubulin 
polymerization assay (IC50 = 3.1 µM). Further mechanism 
studies demonstrated that (±)-19b caused cell cycle arrest in 
the G2/M phase, induced cell apoptosis and depolarized mito-
chondria of K562 cells. And the immunofluorescent assay 
indicated that (±)-19b can effectively disrupt microtubule 
networks in a dose-dependent manner. The wound healing and 
tube formation assays also identified (±)-19b as a novel inhibi-
tor of tubulin polymerization with potent vascular disrupting 
activity. Finally, the in vivo anti-tumor activity of (±)-19b was 
validated in H22 liver cancer xenograft mouse model, which is 
more potent than CA-4. Besides, (R)-(+)-19b and (S)-(-)-19b 
were obtained by chiral separation of (±)-19b and were evalu-
ated for their anti-proliferative and anti-tubulin activities, re-
spectively. (R)-(+)-19b was slightly more potent than (±)-
19b whereas (S)-(-)-19b displayed a significantly decrease 
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5
of activity, which was further elucidated by molecular model-
ling studies. Altogether, (±)-19b may represent a novel class 
of anti-tubulin agent with potent anti-vascular and anti-tumor 
activities and deserves further investigation. 
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